An ABA practice de novo vs acquisition vs partnership decision should match the route to a defined care need, geography, operating capability, capital constraint, and risk tolerance. Compare what each route controls, inherits, and depends on. Use the same evidence window, include transition costs and client impact, and stop any route that lacks clinical leadership, lawful authority, accessible capacity, payer feasibility, or downside liquidity.

Start with the need the practice intends to solve

Amara writes one decision statement before comparing routes: who needs what service, in which setting and geography, by when, and why the current system cannot supply it. The statement names the client and family problem, desired access improvement, clinical model, workforce need, and evidence period. The SBA growth guide advises businesses to test financial readiness and rules that change with location. For ABA, the release packet also covers clinical leadership, qualified supervision, payer configurations, facilities, accessibility, privacy, and continuity.

Compare ABA practice de novo vs acquisition vs partnership routes

A de novo site gives the practice more design control and requires it to create staff, demand, payer access, facilities, and operating routines. An acquisition can supply an existing workforce, clients, contracts, and locations while carrying record, compliance, culture, revenue, and integration risk. A partnership may preserve separate ownership and reduce capital needs while adding dependency, shared-control, referral, data, payment, and exit questions. The SBA acquisition page is general business orientation; the practice still needs healthcare, professional, payer, employment, privacy, tax, and transaction review.

Build a route-comparison record

Use one row per route and record the target population, geography, service, setting, ownership, decision rights, required approvals, accountable clinical leader, staff and supervision plan, payer path, demand evidence, accessible capacity, facility, technology, startup or purchase price, working capital, transition cost, downside case, time to first lawful service, integration work, reversible pilot, stop rule, and evidence owner. Keep optimistic assumptions separate from validated facts.

Use hard gates before scoring preferences

A route remains closed when entity or professional authority is unresolved, a qualified clinical leader is unavailable, accessibility lacks a workable plan, the payer path is speculative, care continuity depends on an untested handoff, or downside cash falls below the approved floor. The DOJ Title III overview addresses equal opportunity, effective communication, reasonable modifications, and physical access for covered public accommodations. Access work belongs in route design, not in an adverse-fit shortcut.

Evaluate acquisition and partnership competition issues early

The current 2023 Merger Guidelines describe federal agency enforcement frameworks and expressly create no independent rights or obligations. They address competition for customers, workers, suppliers, and other providers, and they can apply to partial ownership or a series of acquisitions. Transaction counsel should assess the actual geography, services, labor markets, control rights, information sharing, and filing duties. Deal size alone does not answer the question.

Test the operating model before committing

Amara gives each route a ninety-day evidence plan. The de novo route tests recruiting, payer configuration, site access, and first-day operations. The acquisition route tests records, claims, authorizations, payroll, access rights, and integration capacity. The partnership route tests referral handoffs, response time, communication access, data boundaries, decision rights, and termination. A successful pilot supports only the route, population, location, and conditions actually tested.

Compare reversibility and hidden dependency

Add a reversibility column to the route record. A short lease contingency, limited pilot, or services agreement with a tested termination process may allow an orderly pause. A purchase, custom build, shared brand, cross-entity workforce model, or deeply connected data exchange may be much harder to unwind. Record the earliest commitment that materially reduces choice, the cash and client consequences of reversal, the evidence due before that commitment, and who can stop it.

Dependency matters as much as ownership. A de novo plan may depend on one clinical leader, one landlord approval, or one payer contract. An acquisition may depend on seller transition support, assignable contracts, retained leaders, or a legacy system. A partnership can depend on the other party's referrals, site access, workforce, reputation, or data. Test how service continues if the dependency is late, restricted, or lost. A route that works only in the best case is not ready merely because its headline economics look attractive.

Build a downside clock before the decision meeting

Place the three routes on the same monthly timeline from first spend through stable operations. Show cash committed, cash still reversible, expected service capacity, recruiting and payer milestones, transition work, and the point at which the downside cash floor is crossed. Apply the same delays to all routes so acquisition speed is not compared with a deliberately conservative de novo case. Keep purchase price, working capital, integration cost, and operating loss visible as different uses.

At the decision meeting, each evidence owner confirms the source, date, limitations, and unresolved questions for their section. The clinical leader explains readiness and continuity without being asked to validate price. Finance presents base and downside liquidity without declaring payer or legal authority. Counsel and other qualified advisers address their own domains. The approving group records disagreements, required conditions, and the next review. If a hard gate stays open, the decision can authorize more evidence work but not the irreversible commitment.

Work through a fictional comparison

Amara compares nine fictional route-location combinations. Six clear every clinical, authority, payer, access, capital, and downside gate. One acquisition has no verified payer-change path, one partnership gives the referral source inappropriate control over clinical decisions, and one de novo site falls below the cash floor under the staffing-delay case. One problem repairs. Two routes stay closed. Readiness is 6 of 9, or 66.7%, with all nine retained in the report.

Measure decision quality after the choice

Track forecast assumptions confirmed by the due date, launch gates cleared, time from approval to lawful first service, accessible capacity delivered, qualified positions filled, client transitions completed, unresolved integration items, cash used versus the approved case, and stop rules triggered. Report the original route cohort and later outcomes separately. A faster opening can still be a poor decision if clinical, workforce, access, or cash conditions deteriorate.

Keep compliance work proportionate and explicit

The OIG General Compliance Program Guidance is voluntary and nonbinding. Its risk-assessment, auditing, reporting, and corrective-action concepts can organize comparison work without validating a route or transaction. The SBA buying guide recommends investigation of contracts, leases, cash flow, licenses, permits, financial statements, and tax records with qualified help. ABA diligence adds clinical, payer, workforce, records, privacy, and client-continuity evidence.

Make a decision that can be revisited

The approval memo states the chosen route, rejected routes, controlling assumptions, owners, release conditions, monitoring window, next review, and authority to pause. A change in financing, payer evidence, workforce availability, facility status, leadership, transaction terms, or client impact reopens the comparison. This prevents sunk cost from becoming the reason to proceed.

Related resources

Sources